Nifty
Sensex
:
:
10616.70
35260.54
40.40 (0.38%)
118.55 (0.34%)

Pharmaceuticals & Drugs

Rating :
56/99

BSE: 500087 | NSE: CIPLA

519.15
-0.40 (-0.08%)
15-Nov-2018 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  521.90
  •  525.00
  •  514.45
  •  519.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2661535
  •  13817.36
  •  678.45
  •  507.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 41,881.16
  • 29.76
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 45,013.60
  • 0.58%
  • 2.84

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.74%
  • 0.00%
  • 16.17%
  • FII
  • DII
  • Others
  • 0.73%
  • 13.09%
  • 33.27%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.82
  • 8.30
  • 3.69

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.66
  • 2.84
  • -0.21

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.25
  • 0.18
  • 0.99

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.72
  • 37.07
  • 38.20

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.79
  • 3.84
  • 3.61

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.67
  • 18.50
  • 18.17

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
4,011.90
4,082.41
-1.73%
3,938.99
3,525.05
11.74%
3,697.97
3,582.00
3.24%
3,913.82
3,647.21
7.31%
Expenses
3,309.68
3,278.02
0.97%
3,212.62
2,878.59
11.60%
3,141.10
3,075.76
2.12%
3,095.16
2,969.57
4.23%
EBITDA
702.22
804.39
-12.70%
726.37
646.46
12.36%
556.87
506.24
10.00%
818.66
677.64
20.81%
EBIDTM
17.50%
19.70%
18.44%
18.34%
15.06%
14.13%
20.92%
18.58%
Other Income
132.57
113.33
16.98%
170.11
151.38
12.37%
40.01
22.79
75.56%
52.93
153.49
-65.52%
Interest
44.37
42.02
5.59%
35.09
27.86
25.95%
35.20
33.40
5.39%
9.15
59.33
-84.58%
Depreciation
281.90
302.22
-6.72%
241.00
213.43
12.92%
284.82
632.19
-54.95%
522.35
257.74
102.67%
PBT
508.52
573.48
-11.33%
620.39
556.55
11.47%
199.34
-136.56
-
340.09
514.06
-33.84%
Tax
142.39
137.42
3.62%
173.71
130.77
32.84%
46.15
-75.70
-
-64.23
128.27
-
PAT
366.13
436.06
-16.04%
446.68
425.78
4.91%
153.19
-60.86
-
404.32
385.79
4.80%
PATM
9.13%
10.68%
11.34%
12.08%
4.14%
-1.70%
10.33%
10.58%
EPS
4.68
5.25
-10.86%
5.60
5.08
10.24%
2.22
-0.77
-
4.98
4.66
6.87%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
15,562.68
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
4,960.60
Net Sales Growth
4.89%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
8.04%
 
Cost Of Goods Sold
5,544.71
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
2,347.40
Gross Profit
10,017.97
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
2,613.20
GP Margin
64.37%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
52.68%
Total Expenditure
12,758.56
12,702.34
12,369.97
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
4,215.55
Power & Fuel Cost
-
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
91.71
% Of Sales
-
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
1.85%
Employee Cost
-
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
242.91
% Of Sales
-
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
4.90%
Manufacturing Exp.
-
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
676.85
% Of Sales
-
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
13.64%
General & Admin Exp.
-
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
193.89
% Of Sales
-
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
3.91%
Selling & Distn. Exp.
-
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
339.15
% Of Sales
-
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
6.84%
Miscellaneous Exp.
-
969.00
1,097.01
83.99
497.67
441.10
355.12
194.07
111.96
185.92
339.15
% Of Sales
-
6.39%
7.62%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
6.52%
EBITDA
2,804.12
2,453.37
2,024.32
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
745.05
EBITDA Margin
18.02%
16.19%
14.06%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
15.02%
Other Income
395.62
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
354.49
Interest
123.81
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
52.23
Depreciation
1,330.07
949.81
871.46
754.22
504.71
372.64
330.48
312.22
273.33
167.07
151.79
PBT
1,668.34
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
895.52
Tax
298.02
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
124.50
Tax Rate
17.86%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
13.90%
PAT
1,370.32
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
771.02
PAT before Minority Interest
1,408.52
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
771.02
Minority Interest
38.20
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
0.00
PAT Margin
8.81%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
15.54%
PAT Growth
15.47%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
40.41%
 
Unadjusted EPS
17.48
17.53
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70
9.92

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
4,347.80
Share Capital
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
155.46
Total Reserves
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
4,192.34
Non-Current Liabilities
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
1,104.39
Secured Loans
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
2.79
Unsecured Loans
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
937.45
Long Term Provisions
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
0.00
Current Liabilities
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
2,112.37
Trade Payables
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
757.43
Other Current Liabilities
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
255.44
Short Term Borrowings
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
0.00
Short Term Provisions
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
1,099.50
Total Liabilities
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
Net Block
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
1,992.49
Gross Block
13,042.25
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
2,693.29
Accumulated Depreciation
2,816.17
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
700.80
Non Current Assets
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
2,359.84
Capital Work in Progress
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
366.32
Non Current Investment
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
1.03
Long Term Loans & Adv.
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
0.00
Other Non Current Assets
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
0.00
0.00
Current Assets
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
5,204.72
Current Investments
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
79.02
Inventories
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
1,398.32
Sundry Debtors
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
1,852.86
Cash & Bank
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
62.06
53.39
Other Current Assets
1,599.13
418.17
437.05
145.60
630.63
468.31
622.17
726.59
2,537.33
1,821.13
Short Term Loans & Adv.
1,122.86
807.84
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
1,797.68
Net Current Assets
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
3,092.35
Total Assets
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
374.83
PBT
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
896.84
Adjustment
1,298.59
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
146.53
252.60
Changes in Working Capital
-783.25
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
-708.54
Cash after chg. in Working capital
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
440.90
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
-64.75
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
-580.06
Net Fixed Assets
-495.82
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
-624.70
Net Investments
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
13.43
Others
-7.10
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
31.21
Cash from Financing Activity
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
178.92
Net Cash Inflow / Outflow
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
-26.31
Opening Cash & Equivalents
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
79.70
Closing Cash & Equivalent
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06
53.39

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
73.50
55.82
ROA
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
11.60%
ROE
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
19.07%
ROCE
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
19.82%
Fixed Asset Turnover
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
2.05
Receivable days
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
115.32
118.45
Inventory Days
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
98.17
91.54
Payable days
57.37
48.81
48.67
52.17
44.93
48.58
50.51
56.11
69.48
59.02
Cash Conversion Cycle
101.50
104.20
109.38
112.14
107.41
113.72
123.59
128.78
144.01
150.98
Total Debt/Equity
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
0.22
Interest Cover
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86
18.15

News Update:


  • Cipla’s arm inks agreement with Avenue Therapeutics
    13th Nov 2018, 09:07 AM

    The company’s arm has entered into definitive agreements with two closing stages for a proposed acquisition

    Read More
  • Cipla gets approval from USFDA for Valganciclovir Tablets
    12th Nov 2018, 08:54 AM

    The company’s Valganciclovir Tablets 450mg is AB-rated generic therapeutic equivalent version of Roche’s Valcyte

    Read More
  • Cipla reports 11% fall in Q2 consolidated net profit
    5th Nov 2018, 14:58 PM

    Total consolidated income of the company marginally decreased by 1.22% at Rs 4,144.47 crore for Q2FY19

    Read More
  • Cipla - Quarterly Results
    5th Nov 2018, 12:40 PM

    Read More
  • Cipla receives USFDA's approval for Metoprolol ER Tablets
    29th Oct 2018, 09:28 AM

    Metoprolol ER Tablets 50mg, 100mg, 200mg is AB-rated generic therapeutic equivalent version of Aralez Pharmaceuticals, Inc’s, Toprol XL.

    Read More
  • Cipla’s arm acquires entire stake in Mirren
    23rd Oct 2018, 11:29 AM

    Cipla Medpro South Africa has completed the acquisition of 100% stake in Mirren on October 22, 2018

    Read More
  • Cipla gets final approval for Albendazole Tablets
    24th Sep 2018, 09:11 AM

    Albenza had US sales of approximately $99 million for the 12-month period ending July 2018

    Read More
  • Cipla gets approval from SAHPRA for first-line triple-combination antiretroviral
    12th Sep 2018, 09:01 AM

    The new combination medicine commonly referred to as TLD, is a combination of tenofovir

    Read More
  • Cipla’s arm secures rights to market cancer drug in US
    13th Aug 2018, 11:10 AM

    The company will be marketing the drug in strengths of 150 and 500 mg tablets

    Read More
  • Cipla reports 10% rise in Q1 consolidated net profit
    8th Aug 2018, 16:13 PM

    Total consolidated income of the company increased by 11.77% at Rs 4,109.10 crore for Q1FY19

    Read More
  • Cipla gets approval for Diclofenac Sodium Topical Gel
    7th Aug 2018, 08:45 AM

    Voltaren Gel and its generic equivalents had US sales of approximately $353 million for the 12-month period ending June 2018

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.